Your browser doesn't support javascript.
loading
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.
Seow, Jeffrey; Graham, Carl; Merrick, Blair; Acors, Sam; Pickering, Suzanne; Steel, Kathryn J A; Hemmings, Oliver; O'Byrne, Aoife; Kouphou, Neophytos; Galao, Rui Pedro; Betancor, Gilberto; Wilson, Harry D; Signell, Adrian W; Winstone, Helena; Kerridge, Claire; Huettner, Isabella; Jimenez-Guardeño, Jose M; Lista, Maria Jose; Temperton, Nigel; Snell, Luke B; Bisnauthsing, Karen; Moore, Amelia; Green, Adrian; Martinez, Lauren; Stokes, Brielle; Honey, Johanna; Izquierdo-Barras, Alba; Arbane, Gill; Patel, Amita; Tan, Mark Kia Ik; O'Connell, Lorcan; O'Hara, Geraldine; MacMahon, Eithne; Douthwaite, Sam; Nebbia, Gaia; Batra, Rahul; Martinez-Nunez, Rocio; Shankar-Hari, Manu; Edgeworth, Jonathan D; Neil, Stuart J D; Malim, Michael H; Doores, Katie J.
Afiliação
  • Seow J; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Graham C; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Merrick B; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Acors S; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Pickering S; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Steel KJA; Centre for Inflammation Biology and Cancer Immunology, Department of Inflammation Biology, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Hemmings O; Department of Immunobiology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.
  • O'Byrne A; Centre for Inflammation Biology and Cancer Immunology, Department of Inflammation Biology, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Kouphou N; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Galao RP; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Betancor G; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Wilson HD; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Signell AW; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Winstone H; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Kerridge C; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Huettner I; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Jimenez-Guardeño JM; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Lista MJ; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Temperton N; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Chatham, UK.
  • Snell LB; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Bisnauthsing K; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Moore A; Guy's and St Thomas' R&D Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Green A; Guy's and St Thomas' R&D Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Martinez L; Guy's and St Thomas' R&D Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Stokes B; Guy's and St Thomas' R&D Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Honey J; Guy's and St Thomas' R&D Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Izquierdo-Barras A; Guy's and St Thomas' R&D Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Arbane G; Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Patel A; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Tan MKI; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • O'Connell L; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • O'Hara G; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • MacMahon E; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Douthwaite S; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Nebbia G; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Batra R; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Martinez-Nunez R; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Shankar-Hari M; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Edgeworth JD; Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Neil SJD; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Malim MH; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Doores KJ; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
Nat Microbiol ; 5(12): 1598-1607, 2020 12.
Article em En | MEDLINE | ID: mdl-33106674
Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10-15 d after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how long antibody responses will be maintained or whether they will provide protection from reinfection. Using sequential serum samples collected up to 94 d post onset of symptoms (POS) from 65 individuals with real-time quantitative PCR-confirmed SARS-CoV-2 infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 8 d POS. We show that the kinetics of the neutralizing antibody response is typical of an acute viral infection, with declining neutralizing antibody titres observed after an initial peak, and that the magnitude of this peak is dependent on disease severity. Although some individuals with high peak infective dose (ID50 > 10,000) maintained neutralizing antibody titres >1,000 at >60 d POS, some with lower peak ID50 had neutralizing antibody titres approaching baseline within the follow-up period. A similar decline in neutralizing antibody titres was observed in a cohort of 31 seropositive healthcare workers. The present study has important implications when considering widespread serological testing and antibody protection against reinfection with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / SARS-CoV-2 / COVID-19 Tipo de estudo: Observational_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / SARS-CoV-2 / COVID-19 Tipo de estudo: Observational_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article